Cancer and Anticancer Myths: An Evidence-Based Appraisal of Sweet Potatoes, Alternative Remedies, and Standard Treatment

Cancer and Anticancer Myths: An Experimental Signal Is Not Proof of Patient Benefit

The conclusion in one sentence

Sweet potatoes and many natural products may have nutritional value or show signals in preclinical research, but the evidence does not currently justify claims that they prevent or treat cancer or can replace conventional cancer care. Cancer decisions should still be based on human clinical outcomes and each patient’s individual condition. PMID: 41517157

The sweet-potato claim makes an unjustified leap in evidence

The central point of Professor Ching-Shun Lin’s original analysis was not that sweet potatoes are “bad.” It was that the claim that sweet potato is the “number one anticancer food” has no foundation in human clinical evidence. Current systematic reviews and cell studies still place anticancer findings on sweet potatoes or sweet-potato leaves at the in vitro or preclinical level. They have not shown that eating sweet potatoes shrinks tumors, prolongs survival, or reduces recurrence in humans, so they cannot support an anticancer ranking across foods. PMID: 41517157

Sporamin in sweet potatoes is indeed a storage protein found in the tuberous root, and related studies have examined cells and nude-mouse models. But “the compound is present,” “an experimental model responds,” and “patients with cancer benefit” are three different propositions. Findings from the first two kinds of research cannot be rewritten as proof that sporamin slows the growth or spread of colorectal cancer in humans. PMID: 30061945 PMID: 34113558 PMID: 31333311

The rumor also conflates wild yam, diosgenin, and dehydroepiandrosterone. The literature identifies diosgenin as a starting material for the pharmaceutical semisynthesis of steroids; it must undergo chemical conversion before it can become another steroid compound. This does not mean that sweet potatoes naturally contain dehydroepiandrosterone, much less that they fight cancer through that compound. PMID: 35677108 PMID: 38826718

More importantly, dehydroepiandrosterone is not a protective compound that can simply be labeled “anticancer.” Prospective human data associate higher levels of related endogenous hormones with an increased risk of postmenopausal breast cancer. This supports Professor Lin’s rebuttal of the claim that “sweet potatoes contain dehydroepiandrosterone and therefore prevent breast cancer.” PMID: 16322344 PMID: 23283524

Natural compounds, immune changes, and cancer treatment effects are not interchangeable

Research on Agaricus blazei provides a clear example. An extract can be studied for its effects on immune markers, but a change in an immune measurement does not mean that a tumor treatment works. Although a trial in patients with multiple myeloma observed some immune changes, it found no significant differences in treatment response, survival, or time to subsequent treatment. It therefore cannot establish that Agaricus blazei has been proven to prevent or cure cancer. PMID: 25664323

The same boundary applies to papaya, sea cucumber, taro, enoki mushrooms, fucoidan, and Clinacanthus nutans. The clinical trial of papaya-leaf extract studied chemotherapy-associated thrombocytopenia; the patients continued to receive chemotherapy, and the trial did not show that papaya could replace surgery, radiotherapy, or chemotherapy. Evidence concerning taro and fungal immunomodulatory proteins also remains largely at the preclinical or candidate-compound stage. PMID: 41812092 PMID: 41194974 PMID: 30266655

Soy and flaxseed caution against going to the opposite extreme. Current evidence does not support the claim that moderate soy intake increases breast-cancer risk, and there is limited evidence associating flaxseed lignans with lower risk. Most of these findings, however, concern risk associations or biomarkers and still cannot be translated into a claim that eating these foods treats breast cancer. PMID: 31754945 PMID: 24013641 PMID: 32312713

Symptom relief is not tumor treatment

CBD, laughter, placebo effects, and some supportive interventions may be studied for their ability to improve pain, sleep, nausea, or quality of life. Even when such benefits are demonstrated, they do not automatically become evidence of antitumor efficacy. Pooled evidence on CBD’s antitumor effects comes mainly from preclinical models, while studies of cancer symptoms often combine different cannabis constituents and offer limited high-quality controlled evidence. Claims about symptom care and claims about treating cancer must therefore be kept clearly separate. PMID: 42198443 PMID: 40932699

Placebo and nocebo effects do have psychobiological mechanisms and may influence subjective symptoms, adverse events, and the treatment experience. A limited placebo effect, however, cannot replace cancer treatment with a specific therapeutic effect, nor can it endorse a product that lacks clinical evidence. PMID: 34460317 PMID: 38601115

The greatest danger of an alternative remedy is often substitution and delay

The Gerson therapy, coffee enemas, regimens based on pancreatic enzymes, and other methods promoted as natural cancer cures cannot establish efficacy through celebrity stories or individual recovery narratives. Reliable evidence of benefit is lacking for the Gerson therapy, while coffee enemas carry reported safety warnings including colitis and sepsis. Clinical comparisons of pancreatic-enzyme regimens likewise failed to show the remarkable results claimed in promotional accounts. PMID: 26389464 PMID: 32899046 PMID: 32309489 PMID: 6710988 PMID: 19687327

The real cause for concern is that population data show a higher risk of death when patients replace conventional cancer treatment with unproven alternative therapies. Time lost to such remedies may also delay surgery, chemotherapy, or radiotherapy and thereby worsen the prognosis. This does not dismiss patients’ concerns about adverse effects; it means that every decision must include the potential cost of delay. PMID: 28922780 PMID: 30027204 PMID: 33148535

Conventional treatment is neither “the same for everyone” nor “free of adverse effects.” Radiotherapy after breast-conserving surgery can reduce recurrence and death from breast cancer, and adjuvant chemotherapy can reduce mortality in certain early breast cancers. An individual’s absolute benefit, however, varies with cancer type, stage, tumor characteristics, and baseline risk. The evidence-based position is to weigh these factors for the individual—not to declare treatment wholly ineffective or promise a cure for everyone. PMID: 22019144 PMID: 22152853

When the literature changes, preserve the original and mark the scientific update

Professor Lin’s earlier rejection of “fasting as a cancer cure” remains sound at its core: fasting is not a proven cancer treatment and cannot replace standard therapy. Early clinical literature now examines fasting as an adjunctive strategy, however, so historical statements such as “there is no scientific literature at all” should be marked as having been superseded by updated literature. They should not be rewritten to imply that Professor Lin himself later revised his statement. PMID: 42125729

Cancer-cell dormancy presents a similar situation. Professor Lin noted that dormant cells may evade conventional treatment and later cause recurrence, a biological direction consistent with current research. Scientific progress lies in the fact that researchers are now exploring both awakening and eliminating dormant cells and maintaining them in a safely dormant state. The latter approach should therefore no longer be described as entirely unstudied. PMID: 42282121 PMID: 42271048

An early liquid-biopsy study observed no particular false positives among healthy controls, but that does not mean all multicancer screening tests are free of false positives, false negatives, or overdiagnosis. Later literature continues to identify these as important risks. Screening tools must be evaluated for the cancer type, intended population, and demonstrated clinical benefit. PMID: 28814544 PMID: 41527449

A reusable checklist for anticancer claims

When you encounter “anticancer” information, first ask whether the study involved cells, animals, healthy people, or patients with cancer. Then ask whether its endpoint was the concentration of a compound, an immune marker, a symptom, or a clinically meaningful outcome such as tumor response, recurrence, or survival. Finally, check whether the product, dose, and method used in the study truly match the food or supplement being advertised.

A claim based on a single case, a celebrity testimonial, a culture-dish result, an animal model, or an attractive mechanism diagram can generate only a hypothesis; it cannot prove efficacy in humans. The risk is still greater if the claim also urges people to stop surgery, chemotherapy, radiotherapy, or another standard treatment. Such decisions should first be discussed with a medical team familiar with the cancer type and stage. The most important way to respect Professor Lin’s original article is to preserve his historical opposition to unjustified leaps in evidence and delays in treatment while honestly marking the literature as updated when new research emerges.